摘要
目的研究卡瑞丽珠单抗联合培美曲赛和顺铂治疗局部晚期非小细胞肺癌(NSCLC)的临床效果。方法选取2019年3月至2021年2月连云港市第二人民医院收治的62例局部晚期NSCLC患者,采用奇偶数字法分为对照组(给予培美曲赛和顺铂治疗,31例)和研究组(给予卡瑞丽珠单抗联合培美曲赛和顺铂治疗,31例)。比较两组患者的近期疗效,以及治疗前后肿瘤标志物[癌胚抗原(CEA)、血管内皮生长因子(VEGF)、细胞角蛋白19片段抗原(CYFRA21-1)]水平;比较两组患者治疗期间的不良反应发生率及生存率。结果研究组客观缓解率(45.16%)、临床控制率(83.87%)均高于对照组(分别为19.35%、54.84%),差异有统计学意义(P<0.05)。研究组治疗后CEA、VEGF及CYFRA21-1均低于对照组(P<0.001)。两组患者治疗期间胃肠道反应、白细胞减少、皮疹、贫血总发生率差异均无统计学意义(P>0.05)。随访结束,研究组生存率高于对照组(76.67%vs.48.28%),差异有统计学意义(P<0.05)。结论卡瑞丽珠单抗联合培美曲赛和顺铂治疗NSCLC可提高临床疗效,降低肿瘤标志物水平,安全可靠,并可提高患者近期生存率。
Objective To observe the clinical effect of camrelizumab combined with pemetrexed and cisplatin in the treatment of locally advanced non-small cell lung cancer(NSCLC).Methods A total of 62 patients with locally advanced NSCLC who were treated in Lianyungang Second People s Hospital from March 2019 to February 2021 were selected and divided into a control group(treated with pemetrexed and cisplatin,31 cases)and a study group(treated with cardamom)by digital parity method.Reliximab combined with pemetrexed and cisplatin,31 cases).The short-term curative effect of the two groups of patients was compared.The levels of tumor markers[carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF)and cytokeratin 19 fragment antigen(CYFRA21-1)]were compared before and after treatment.Adverse reactions during treatment were compared.The survival rates of the two groups were compared.Results The objective remission rate and clinical control rate of the study group were higher(45.16%vs.19.35%,83.87%vs.54.84%,P<0.05).After treatment,CEA,VEGF and CYFRA21-1 in the study group were lower than those in the control group(P<0.001).There was no significant difference in the total incidence of gastrointestinal reactions,leukopenia,rash and anemia between the two groups during treatment(P>0.05).By the end of the follow-up,the survival rates of the study group and the control group were 76.67%and 48.28%,respectively.The survival rate curves of the two groups were compared,and the difference was statistically significant(P<0.05).Conclusions Camrelizumab combined with pemetrexed and cisplatin in the treatment of NSCLC can improve the clinical efficacy,reduce the level of tumor markers,is safe and reliable,and can improve the short-term survival rate of patients.
作者
张新月
陈慧娟
白巧红
吉宁飞
ZHANG Xinyue;CHEN Huijuan;BAI Qiaohong;JI Ningfei(Department of Respiratory and Critical Care Medicine;Department of Oncology,Nanjing Second Hospital Affiliated to Nanjing University of Traditional Chinese Medicine,Nanjing 210003,China)
出处
《中国肿瘤外科杂志》
CAS
2022年第6期567-570,575,共5页
Chinese Journal of Surgical Oncology
关键词
卡瑞丽珠单抗
晚期
非小细胞肺癌
疗效
生存
Camrelizumab
Advanced
Non-small cell lung cancer
Efficacy
Survival
